p38 MAPK inhibitors: a patent review (2012 – 2013)
- 10 March 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 24 (5), 535-554
- https://doi.org/10.1517/13543776.2014.894977
Abstract
The p38 MAPK is a ubiquitous target in the research-based pharmaceutical industry. It plays a decisive role in the regulation of the production of proinflammatory cytokines. Since novel biological therapies have revolutionized the treatment of chronic inflammatory diseases, an intensive global search is underway for small molecules for the same application. Herein, the patents and the corresponding publications of international companies, which focus on the development and identification of a new generation of small-molecule p38 inhibitors, are summarized. The most promising approach is the development of linear binders, which induce a glycine flip at Gly110 of the kinase hinge region by a carbonyl oxygen atom of the respective ligand. The major focus of the patent works was the application of molecules in new indications. Previous applications were in the treatment of rheumatoid arthritis; currently, there are several new applications, including pulmonary diseases, cancer and Alzheimer's disease. Targeting p38 upstream kinases and downstream effectors has also proved to be a very promising step in the development of more effective inhibitors. A further trend is drug combination, applied to a wide range of indications, such as chronic obstructive pulmonary disease and cancer.Keywords
This publication has 38 references indexed in Scilit:
- Novel triazolopyridylbenzamides as potent and selective p38α inhibitorsBioorganic & Medicinal Chemistry Letters, 2012
- Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary DiseaseJournal of Medicinal Chemistry, 2011
- p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)Expert Opinion on Therapeutic Patents, 2011
- Substituted N-aryl-6-pyrimidinones: A new class of potent, selective, and orally active p38 MAP kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2011
- Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinaseBioorganic & Medicinal Chemistry Letters, 2011
- Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory DiseasesJournal of Medicinal Chemistry, 2010
- "Go upstream, young man": lessons learned from the p38 sagaAnnals Of The Rheumatic Diseases, 2009
- Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinaseBioorganic & Medicinal Chemistry Letters, 2009
- Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modesBioorganic & Medicinal Chemistry Letters, 2008
- The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007